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γ-secretase in renal carcinoma
Zhen Guo1, Xunbo Jin1* and Haiyan Jia2Abstract
Background: Our study is to research the effect of inhibited ADAM-17 expression through the Notch pathway in
renal carcinoma.
Methods: Immunohistochemistry and western blot were used to examine the expression of ADAM-17 protein in
renal cancer tissues. Proliferation and cell invasion of 786-o cells, as well as OS-RC-2 cells, after treatment with two
different inhibitors of the Notch pathway, were examined by CCK-8 assay and Transwell assay, respectively. 786-o cell
apoptosis was measured using the FCM test.
Results: ADAM-17 was highly expressed in RCC tissues. Compared with blocking γ-secretase, a known mechanism of
impairing Notch, blockade of ADAM-17 more effectively down-regulated the expressions of Notch1 and HES-1
proteins. Similarly, we found that the ADAM-17 inhibitor, Marimastat, could more efficiently reduce renal cell
proliferation and invasive capacity in comparison with the γ-secretase inhibitor DAPT when used at the same dose.
Similar results were obtained when apoptosis of 786-o was measured.
Conclusion: Compared with γ-secretase, inhibition of ADAM-17 expression more effectively inhibits Notch
pathway-mediated renal cancer cell proliferation and invasion. ADAM-17 may be a new target for future
treatment of renal carcinoma.
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The molecular mechanisms underlying renal carcinoma
(RCC) are still unclear. Moreover, because RCC easily
metastasizes, despite conventional treatments the prog-
nosis remains poor. Apoptosis and cell differentiation of
RCC is believed to be controlled by multiple cell path-
ways. Thus, much research is focused on developing
targeted therapies at the molecular level of RCC.
Current research of the Notch signaling system is
mostly focused on the pathway and its corresponding
target genes, while little research is centered on activa-
tion of the Notch pathway. To this end, it is known that
the Notch signaling pathway is activated by a 3-step pro-
teolysis process involving three proteolytic cleavage sites* Correspondence: 944172919@qq.com
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reproduction in any medium, provided the orknown as S1, S2 and S3 [1-3]. Proteolysis on the S2 site,
which is critically affected by the key enzyme ADAM-17
(also called TACE), is especially overlooked. The
ADAM-17 gene is located on human chromosome 2
(2p25) and rat chromosome 12. It is 50 kb in length and
composed of 19 exons. It has a similar structure to most
ADAMs with a front control region, metalloproteinase
peptidase region, integrin-splitting region, cysteine-rich
region, transmembrane region and intracellular region
[4,5]. ADAM-17 plays a crucial role in the development
of epithelial tumors. High expression of ADAM-17 may
further increase release of epidermal growth factor
receptor (EGFR) ligands including EGF, androgen recep-
tor (AR), heparin-binding (HB)-EGF, transforming growth
factor (TGF-α) and epiregulin (EPR), that result in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role in cleaving the S2 site in the Notch signal pathway.
The enzyme γ-secretase has also been found to trigger
activation of the Notch pathway by splitting the S3 site.
According to the research of Zhu [6], blockade of γ-
secretase inhibits activation of the Notch pathway. In
contrast to ADAM-17, which cleaves the S2 site in the
extracellular region, γ-secretase acts on a transmem-
brane region. Thus we hypothesized that because of
increased accessibility to the extracellular region the
inhibition of ADAM-17 could more significantly down-
regulate Notch activation, than that of γ-secretase. Test-
ing of this hypothesis confirmed that ADAM-17 is a key
enzyme for the activation of the Notch signal pathway.
Moreover, inhibition of its activity more effectively pro-
motes apoptosis and impairs invasive ability in RCC
than that of γ-secretase with DAPT. Therefore, the
ADAM-17 inhibitor Marimastat is a better targeted in-
hibitor of the Notch pathway than the γ-secretase in-
hibitor, DAPT.Materials and methods
Collection of primary clear cell renal carcinomas
Sixty-seven pairs of clear cell renal carcinoma (CCRCC)
tissues and 10 adjacent normal kidney tissues were col-
lected at the Department of Urology of the Shandong
Provincial Hospital of China. All RCC cases were con-
firmed clinically and pathologically to be of the clear cell
type. All tumor specimens were staged based on the
2002 AJCC TNM classification of malignant tumors
(Table 1). The samples were snap-frozen in liquid nitro-
gen and stored at −80°C until analysis. Prior written
informed consent was obtained from all patients and the
study was approved by the Protection of Human Sub-









TNM stage 16.39 <0.01
I 14 3 11
II 22 14 8
III 25 21 4
IV 6 5 1
Rate 64.18% 35.82%
64.18% of positive expression of ADAM-17 was recorded in all 67 cases of
renal carcinoma tissues, there are 26 positive cases in stage-III and stage-IV
renal carcinoma and 5 negative cases, which indicates that ADAM-17
expression is more in high stages of RCC; despite the low expression rate in
stage-I renal carcinoma, the ADAM-17 expression is increased as the tumor
stage increasing(χ2=16.39, P<0.01).Immunostaining
Formalin-fixed, paraffin-embedded tissue sections were
dewaxed in xylene, rehydrated in graded alcohols, and
briefly microwaved in 0.001 mol/L citrate buffer (pH 6),
to optimize antigen retrieval. Sections were then used to
detect ADAM-17 using the Histostain-plus kit (BD
Science, NY, US) according to the manufacturer’s
instructions. The primary antibody of activated ADAM-
17 (Abcam Ltd. Cambridge, UK) was diluted 1:500. Im-
munostaining was visualized using a Nikon microscope.
The criteria of ADAM-17 positive expression are the
more than 3 cells can be stained to the brown color at
least three randomly selected 20xfields, however the
negative is no staining.Cell culture and reagents
The CCRCC cell lines 786-O and OS-RC-2 were pre-
served in our laboratory. The cells were cultivated in
RPMI 1640 medium and Dulbecco’s modified Eagle’s
medium (Aidlab Biotechnologies Co. Beijing, China), re-
spectively, and supplemented with 10% fetal calf serum
in a humidified incubator at 37°C with a mixture of 95%
air and 5% CO2.
Cell treatment and grouping
We treated the 786-O and OS-RC-2 cells with ADAM-
17 inhibitor, Marimastat (Tocris, UK) at concentrations
of 1 μmol/L, 2 μmol/L and 3 μmol/L diluted in 1640
medium to a final volume of 2 ml, or the same concen-
trations of the γ-secretase inhibitor, DAPT (EMD bio-
science, CA) for 24 hours. The control group was
provided by cells incubated with 2 ml of 1640 medium
alone. Afterwards cells were collected for further testing.
Western blot
786-O cells and OS-RC-2 cells were lysed in radio-
immunoprecipitation assay buffer and equal amounts of
the protein extracts (30 μg per lane) were separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Proteins were then transferred onto polyvinylidene fluoride
membranes (Millipore, Billerica, MA) for western blotting.
The primary antibodies against NOTCH1 (activated Notch
intracellular domain), HES-1 (Abcam, Cambridge, MA),
and β-actin (Aidlab Biotechnologies Co., Beijing, China)
were incubated with membranes overnight at 4°C. After
3 washes, for 15 min each, in Tris-buffered saline
supplemented with 0.1% Tween 20, membranes
were incubated with peroxidase-conjugated goat anti-
mouse/rabbit IgG antibodies (Aidlab Biotechnologies
Co. Beijing, China) for 1 h at room temperature. The
bound anti-bodies were visualized by an enhanced
chemiluminescence detection system using medical
X-ray films.
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8 assay
Cells were seeded in a 96-well plate at approximately
8×104 in a volume of 100 μl/well. Wells were also pre-
pared that contained known numbers of four kinds of
cells to be used to create a calibration curve. To measure
apoptosis, 10 μl of the CCK-8 solution (Dojindo, Japan)
was carefully added to each well of the plate. The plate
was incubated for 1–4 h in the incubator during which
time the absorbance was measured at 450 nm using a
microplate reader at 30, 60, and 90 min.Transwell assay for cell invasion
Cell invasive ability was determined using the Transwell
test kit (Corning, NY, USA). Briefly, matrigel was mixed
with 1640 medium at a ratio of 1:7 and 100 μl was added
to each upper-transwell then placed into the incubator for
1 hour for the mixture to set. Then, 786-O cells were
serum-starved for 12 h in pre-warmed 1640 media alone
to eliminate the effects of serum. Twenty-four hours after
the application of matrigel, 600 μl of 10% FBS solution
was added to the lower transwell. The serum starved cells
were resuspended to a density of 2.5×105 in 1640 solution
without FBS in a final volume of 1 ml, with or without
Marimastat or DAPT. From this, 100 μl was added to each
transwell (2.5×104). After 48 h in the incubator, the
transwell casters were purged into PBS to remove the
non-adherent cells, and then submerged it in 4% parafor-
maldehyde for 10 min for fixation, and finally replaced in
PBS. After the membrane was dried, cells were observed
and counted under a microscope (400×).
Flow cytometry and cell cycle apoptosis
1×106 cells were plated in 100 ml culture flasks and allowed
to proliferate until 70–80% confluence was attained. Cells
were then treated with Marimastat (1 μmol/L or 3 μmol/L),
DAPT (1 μmol/L or 3 μmol/L), or DMSO (15 μl) as con-
trol. After 24 h, cells were washed then resuspended in
PBS. To measure apoptosis, the Annexin-FITC Apoptosis
Detection Kit (KAIJI BIOTECH, Nan Jing, CN) was used
according to its instructions. Briefly, fresh cells were labeled
with 1:500 diluted Annexin V-biotin conjugated with FITC
followed by incubation with 1:1000 diluted PI. Annexin
V-PI expression levels were measured by FACS Calibur
(BD Science, NY, USA) and analyzed by Modfit Software.
Statistical analysis
All data were analyzed using the SPSS statistical software
package (SPSS Inc., Chicago, IL) All data were expressed
as mean ± standard deviation (SD) unless otherwise speci-
fied. Intergroup differences for two variables were assessed
by unpaired t-test. Differences in parameters between
groups were evaluated by ANOVA followed by unpairedt test with Bonferroni correction for multiple compari-
sons. P<0.05 was considered statistically significant.Results
ADAM-17 is over expressed in renal carcinoma tissues
Through immunohistochemical staining assay we found
that ADAM-17 was highly expressed in renal carcinoma
tissues. Specifically, we observed 43 positive cases
among a total of 67 cases (64.18%) (Figure 1A and B).
The expression rate in the T1–T4 stages were 21.43%,
63.67%, 84.00% and 83.33%, respectively. ADAM-17 was
highly expressed as the tumor stage increased, in the
stageI, only 3/14 tissues were ADAM-17 positive but in
the stage III and IV, the ADAM-17 positive tissue were
increased to 21/25 and 5/6. To evaluate these results, we
found that the positive expression rate of ADAM-17 was
greater in the high tumor stage than low tumor stage
(×2 = 16.39 P<0.01) (Table 1). In contrast, it was hardly
expressed in non-renal carcinoma tissues. Indeed, from
a total of 67 samples, only one sample was positive,
resulting in a positive expression rate of 1.49% (P<0.05
data was not shown).
Effects of the ADAM-17 inhibitor Marimastat and the
γ-Secretase inhibitor DAPT on protein expression of
Notch 1 and HES-1
After treatment with either Marimastat or DAPT, the ex-
pression of Notch 1 and HES-1 proteins in 786-O and OS-
RC-2 cells was examined by western blot. The Notch1 and
Hes-1 protein level was measured by the concentration of
the test group subtracted from the control group. We
found that regardless of whether cells were treated by
Marimastat or DAPT, expression of Notch 1 and HES-1
proteins was considerably decreased (P<0.05) (Figure 1C
and D). The protein level of Notch1 and Hes-1 treated by
Marimastat or DAPT were shown by (Figure 2A and B). In-
deed, in 786-O cells, Notch 1 and HES-1 protein levels in
768-O cells treated by Marimastat decreased 0.397±0.126
and 0.411±0.096, respectively, while DAPT-treatment pro-
duced 0.364±0.068 and 0.391±0.099 decreases in Notch 1
and HES-1, respectively. Similar results were found in the
OS-RC-2 cells, where Marimastat treatment decreased
protein expression by 0.405±0.086 for Notch 1 and
0.414±0.909 for HES-1, whereas DAPT treatment de-
creased protein levels by 0.221±0.107 and 0.348±0.108 for
Notch-1 and HES-1, respectively. Thus, the expression of
Notch 1 and HES-1 proteins was more readily decreased in
the Marimastat treated renal carcinomas than in those
treated by DAPT. Notably, the same concentrations of each
inhibitor were used for treatments. Further analysis revealed
that Marimastat treatment more significantly decreased the
two proteins than DAPT treatment (786-O Notch1 P<0.05
Hes-1 P<0.05; OS-RC-2 Notch1 P<0.05 Hes-1 P<0.05)
Figure 1 Immumohistochemical staining of ADAM-17 in renal carcinoma tissues. A: Normal kidney tissue stained by ADAM-17. B: Renal
carcinoma tissue (stage-III) with ADAM-17 concentrated around the cytomembrane stained red (arrowed). C: Expression of Notch1 and HES-1
protein as measured by Western blot analysis after treatment with Marimastat or DAPT, or a media alone control, in 786-O cells. D: Expression of
Notch1 and HES-1 protein levels by Western blot after treatment with Marimastat or DAPT, or a media alone control, in OS-RC-2 cells.
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ively inhibits activation of the Notch pathway.
The impact on invasion of 786-O and OS-RC-2 cells is
greater with the ADAM-17 inhibitor Marimastat than the
γ-secretase inhibitor DAPT
After treatment of the two cell lines with different doses
of either Marimastat or DAPT (1–3 μmol/L), we found
the ODs were readily decreased in both cell lines when
compared with the DMSO treated control. Moreover, we
found that the mean OD value of Marimastat-treated
786-O cells was lower than that for cells treated with the
same dose of DAPT (1 μmol/L = 0.529 vs 0.579; 2 μmol/
L = 0.502 vs 0.549; 3 μmol/L = 0.446 vs 0.495; and con-
trol group = 0.589 vs 0.672). Similar results were
obtained using OS-RC-2 cells (1 μmol/L = 0.514 vs
0.533; 2 μmol/L = 0.442 vs 0.477; 3 μmol/L = 0.340 vs
0.428; and control group = 0.566 vs 0.536). Statistical ana-
lysis revealed that the two inhibitors both significantlydecreased the invasive ability (P<0.05, P<0.05) (Figure 3A
and B). However, under the same dose conditions,
Marimastat rendered a greater impact on the two types of
renal carcinoma cell lines than did DAPT (P<0.05).
ADAM-17 inhibitor Marimastat more effectively impairs
invasion of 786-O cells than the γ-secretase inhibitor
DAPT
We tested the invasive capacity of the renal carcinoma
cells, 786-O, treated with either Marimastat or DAPT at
concentrations of 1 μmol/L, 2 μmol/L, and 3 μmol/L, by
Transwell assay. Treatment with either Marimastat or
DAPT reduced the number of 786-O invasive cells in a
dose-dependent manner when compared with the non-
treated control group (Figure 3C). Notably, the drug-
induced reduction in invasive cell number was significantly
more potent with Marimastat treatment than with DAPT
(Table 3) (p<0.05). Thus we demonstrated that with the
same dose, the ADAM-17 inhibitor Marimastat more
Figure 2 Expression of Notch1 and HES-1 proteins in 786-O and OS-RC-2 cells. A: Expression of Notch1 and HES-1in 786-O cells after
treatment with Marimastat, DAPT, or control. B: OS-RC-2 cells were treated and analyzed as in ‘A.’
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Secretase inhibitor DAPT.
ADAM-17 inhibitor Marimastat more effectively increases
the apoptosis rate in 786-O cells than the γ-secretase
inhibitor DAPT
To study the effect of Marimastat and DAPT on the
apoptosis of 786-O, Annexin-V-PI staining and flow
cytometry were conducted after cells were treated with
inhibitors (1 μmol/L and 3 μmol/L treatment), or DMSOTable 2 The decrease protein level of Notch1 and Hes-1 after
Notch1 with Marimastat Notch1 with DAPT P
786-O cell 0.397±0.126 0.364±0.068 P
OS-RC-2 cell 0.405±0.086 0.221±0.107 P
The expression of Notch 1 and HES-1 proteins was more readily decreased in the M
(786-O Notch1 P<0.05 Hes-1 P<0.05; OS-RC-2 Notch1 P<0.05 Hes-1 P<0.05).as a control. Analysis of Annexin V-PI staining showed
apoptotic rates of 3.4% and 5.4% for 786-O after DAPT
treatment with 1 μmol/L and 3 μmol/L, respectively
(Figure 4A and C), and 4.5% and 7.7% following
Marimastat treatment with the same doses (Figure 4B
and D). Lower levels of apoptosis (2.8%) were detected
in the control group (Figure 4E). The following statistical
analysis showed that the apoptosis rates of 786-O after
Marimastat treatment was greater than that attained
after treatment with DAPT at the same concentrationstreatments in renal cell lines
value Hes-1 with Marimastat Hes-1 with DAPT P value
<0.05 0.411±0.096 0.391±0.099 P<0.05
<0.05 0.414±0.909 0.348±0.108 P<0.05
arimastat treated renal carcinomas than in those treated by DAPT
Figure 3 Inhibition of either ADAM-17 or γ-secretase reduces proliferation of renal carcinoma cell lines. A–B: 786-O (A) and OS-RC-2 (B)
were treated with either Marimastat or DAPT at different doses then proliferation was measured by CCK-8 assay, the control group is no
treatment. The mean cell activity (OD) of three experiments is presented (P<0.05). C: Expression of 786-O cells in the transwell assay by different
doses of two types of inhibitor treatment cells.








In the Transwell assay, the number of 786-o cells penetrating Matrigel
decreased with the increasing concentration of Marimastat and DAPT, whereas
Marimastat had more effect under the same concentration(P<0.05), which
indicates that MARIMASTAT is more capable of thwarting the invasion of
786-o cells.
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inhibitor Marimastat exhibits higher specificity and
greater impact on the apoptosis rate of 786-O than the
γ-secretase inhibitor DAPT.
Discussion
Notch signaling and its receptor play an important role
in tumor occurrence and development [7-9]. Because
this pathway signals for cell apoptosis and revasculariza-
tion in renal carcinoma, many researchers focus on the
inhibition of Notch. Sjölund’s and later researchers have
shown that activation of the Notch pathway reinforces
invasion of renal carcinoma [10-14]. ADAM-17 which is
the key enzyme has been reported to be highly-
expressed in renal carcinoma in the mRNA level in 27
Figure 4 The effect of Marimastat and DAPT on apoptosis of renal carcinoma cells. A–E: Flow cytometry was performed after Annexin-PI
staining to observe the 786-O apoptosis rate after treatment with either of the two inhibitors at two doses. 1 μmol/L DAPT (A) and Marimastat
(B); 3 μmol/L DAPT (C) and Marimastat (D); DMSO control (E).
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carcinoma tissues were examined and found to express
high levels of ADAM-17 in different TNM stages, espe-
cially the advanced stages, T3 and T4. Because ADAM-
17 is involved in Notch activation, this finding suggests
that ADAM-17 activation of Notch correlates with RCC
progression. Indeed, Aparicio’s and Buzkulak’s research
demonstrated that Notch 1 protein levels increase in
renal carcinoma in association with clinical staging
[16,17]. These findings manifest the important role of
the Notch pathway in the development of renal carcin-
oma. In our research, we demonstrate that high expres-
sion of ADAM-17 is closely related to the malignancy of
renal cancer. Moreover, the consistent expression trend
of ADAM-17 and Notch1 proteins suggest that a posi-
tive relationship exists between the two.
Marimastat is the only metalloprotease considered to
be able to inhibit the ADAM-17 protein [18]. By
Murthy’s research, it was demonstrated that ADAM-17
could suppress the activation of the Notch signal system
[19]. Furthermore, Marimastat has been acknowledged
for its impact on tumors through down-regulation of the
Notch pathway by inhibiting ADAM-17. A growing
number of new ADAM-17 inhibitors have also emerged
in recent years including IK682 [20]. The recent research
on γ-secretase inhibitors has revealed that it may also
work as a Notch pathway inhibitor and be useful in
treatment of malignant tumors where this pathway isderegulated [21,22]. In our research, both Marimastat
and DAPT down-regulated the expression levels of
Notch1 and HES-1 proteins. Indeed, our data demon-
strates that these two drugs inhibit the Notch pathway
in a dose-dependent fashion (Figure 1C and D). Import-
antly, we found that Marimastat more effectively blocked
the Notch pathway, when compared with the effects of
DAPT at the same dose. This suggests that in RCC cell
lines, blocking ADAM-17 can decrease expression of the
Notch pathway and its downstream target genes, more
efficiently than γ-secretase inhibition.
The Notch pathway has been published to induce
tumor proliferation and increase invasiveness. For ex-
ample, Wu reported that in breast cancer, the Notch
pathway can induce the proliferation and invasion
[23,24]. We used Marimastat and DAPT for the targeted
inhibition of ADAM-17 and γ-secretase, respectively.
We observed that proliferation of 786-O and OS-RC-2
RCC cells was significant decreased after treatment with
either inhibitor, especially after use of greater concentra-
tions. This suggests that in RCC cell lines, inhibition of
the Notch pathway can reduce the proliferative ability.
Importantly, when treatment effects of Marimastat and
DAPT, used at the same concentrations, were compared,
Marimastat was found to more significantly decrease
proliferation than DAPT. This trend also appeared in
the transwell invasion assay performed using 786-O
cells, where the number of cells able to pass through the
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with Marimastat than DAPT at the same concentration
(Figure 3C). Thus, our data confirms that in RCC,
inhibiting the Notch pathway can cause inhibition of cell
proliferation and decrease invasive capacity. For the first
time, we demonstrated that the effect of ADAM-17 inhib-
ition is better than that achieve by inhibition of
γ-secretase in RCC cell lines. In our flow cytometry assay,
it was clearly found that inhibition of the Notch pathway
through the two types of inhibitors caused increased
apoptosis (Figure 4), where again the effect of Marimastat
was more pronounced than that of DAPT. Thus, our data
suggest that inhibition of the Notch signaling pathway can
impair both proliferation and cell invasion ability, and in-
crease the apoptosis rate of RCC. These effects were best
when ADAM-17 was suppressed using Marimastat than if
the γ-secretase inhibitor DAPT was used, suggesting that
Marimastat is a highly potent inhibitor of the Notch
pathway.
In our research, we reveal that blocking the expression
of ADAM-17, which is needed for activation of Notch
via cleavage of the S2 site, is more specific and effective
than inhibition of γ-secretase-mediated cleavage of the
S3 site in RCC. We believe that the reason for this is
that as ADAM-17 is not a transmembrane protein, acti-
vation of ADAM-17 could lead to the stimulation of a
variety of intracellular pathways including the Notch
pathway and its activators, such as G-protein coupled
receptors (GPCR) and PKC [25]. Thus inhibition of
ADAM-17 may suppress other intracellular pathways
which can affect the Notch pathway such as EGFR [26].
Another reason why Marimastat exhibited superior
ability to decrease the malignant phenotype, could
be because the S3 sites in Notch that are cut by
γ-secretase are located in the transmembrane region,
and are therefore only activated downstream of the
Notch pathway. Therefore, inhibition of ADAM-17 can
relay a better and more specific effect, and the ADAM-
17 inhibitor Marimastat appears to be a better targeted
inhibitor. We expect that the results of this study can
provide a new way for a future targeted therapy treat-
ment against RCC especially through inhibition of the
Notch signal system.Competing interest
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